Get the Stockscreener App
1.44
15.20%
0.19
Pre-market:
1.37
-0.07
-4.86%
Bone Biologics Corp stock is traded at $1.44, with a volume of 122.98K.
It is up +15.20% in the last 24 hours and up +13.39% over the past month.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
122.98K
Relative Volume:
8.58
Market Cap:
$2.59M
Revenue:
-
Net Income/Loss:
$-2.86M
P/E Ratio:
-0.5744
EPS:
-2.5071
Net Cash Flow:
$-2.57M
1W Performance:
+15.20%
1M Performance:
+13.39%
6M Performance:
-28.36%
1Y Performance:
-69.81%
1-Day Range:
$1.23
$1.48
1-Week Range:
$1.21
$1.48
52-Week Range:
$1.05
$6.75
Bone Biologics Corp Stock (BBLG) Company Profile
Name
Bone Biologics Corp
Sector
Industry
Phone
(781) 552-4452
Address
2 BURLINGTON WOODS DRIVE,, BURLINGTON
Compare BBLG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBLG
Bone Biologics Corp
|
1.44 | 2.59M | 0 | -2.86M | -2.57M | -2.5071 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bone Biologics Corp Stock (BBLG) Latest News
BBLG | Bone Biologics Corp Common Insider Trading - Quiver Quantitative
BBLG Q1 2026 Earnings: EPS Beat on Narrower Loss, Stock Dips SlightlyDiluted EPS Report - newsline.com
Bone Biologics Corp (BBLG) Edges Lower Amid Light Trading – Key Support Level in FocusBreadth Thrust - newsline.com
Bone Biologics Corp Warrants (BBLGW) Remains Steady at $14.0, Navigating Key Support and Resistance LevelsEnding Diagonal - newsline.com
Bone Biologics Corp Warrants (BBLGW) Surge Over 9%: Key Levels and OutlookOBV Trend Line - newsline.com
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Asia Demineralized Bone Matrix Allograft MaterialsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
NUWE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
World Demineralized bone matrix allograft materialsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
BBLG Q1 2026 Earnings: Smaller-than-Expected Loss on No Revenue as Bone Graft Developer Continues R&D ProgressGAAP Earnings Report - The Legal Advocate
Bone Biologics Corp (BBLG) Surges 5.24% — Can It Hold Above Key Resistance?Factor Rotation - The Legal Advocate
Bone Biologics Corp (BBLG) Tests Support After Marginal DeclinePCR Mean Reversion - newsline.com
Bone Biologics Corp (BBLG) Rises 3.28% as Stock Approaches Resistance LevelFundamental Weighted - The Legal Advocate
Bone Biologics Corp Warrants (BBLGW) Holding Steady at $14.15 After a Flat SessionBullish Pattern Stocks - The Legal Advocate
World Bone Graft SubstitutesMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss as Company Advances Bone Graft PlatformROIC Trend Report - Newser
BBLG Q1 2026 Earnings: Narrowed Loss Beats Estimates as Bone Biologics Advances PipelineBook Value Growth - The Legal Advocate
BBLG Q1 2026 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesAI Trading Community - Newser
Bone Biologics Corp (BBLG) Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares DipSocial Signal Watchlist - Newser
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss as Bone Biologics Advances DevelopmentFree Stock Community - Newser
Bone Biologics extends rhNELL-1 protein shelf life to 29 months - Investing.com
Spine fusion protein from Bone Biologics now lasts 29 months - Stock Titan
VBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VBIO PE Ratio & Valuation, Is VBIO Overvalued - Intellectia AI
Bone Biologics (BBLG) flags going concern, cash runway into Q4 2026 - Stock Titan
TradingKey - TradingKey
Bone Biologics Corp expected to post a loss of 54 cents a shareEarnings Preview - TradingView
How Bone Bio (BBLG) translates market opportunities into growth (-3.01%) 2026-05-08Corrective Wave - newsline.com
What Bone Bio (BBLG) is doing that smarter investors notice (Smart Money Exits) 2026-05-07Stock Community Signals - Newser
What Bone Bio BBLG is doing that smarter investors notice Smart Money Exits 20260507Profit Announcement - Newser
Why Bone Bio (BBLGW) is trading below its true worth (Investor Concern) 2026-05-06Stock News - newser.com
Leading Companies Fueling Growth and Innovation in the Spine Biologics Market - openPR.com
BBLGW (Bone Bio) quarterly earnings release excludes core financial metrics, investors seek additional operational disclosures.Revenue Guidance Range - newsline.com
Bone Bio (BBLG) Stock: Volatility Overview (-1.78%) 2026-04-23Crowd Sentiment Stocks - Newser
BBLGW (Bone Bio) quarterly earnings carry no finalized public metrics as the firm wraps up internal financial reviews.Community Sell Signals - Newser
BBLGW (Bone Bio) quarterly earnings data unavailable, stakeholders await updates on core orthobiologics growth plans.Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Orthobiologics Market - openPR.com
Is First Mid (FMBH) stock still a good play today (Flirts with Breakout) 2026-04-20Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai
Aug Weekly: What is Bone Biologics Corporation Equity Warrants revenue forecastExit Point & Fast Moving Market Watchlists - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
Entry Recap: What is the Moat Score of Bone Biologics CorporationQuarterly Performance Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars - PharmiWeb.com
Is Bel Fuse (BELFB) Stock at a Peak | Price at $204.62, Down 0.01%Community Driven Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
BBLGW Stock Analysis: Bone Biologics Corp Warrants Flat at 21 Amid Calm Biotech Trading - The Legal Advocate
Market Structure, Emerging Trends, and Key Player Analysis in the Orthobiologics Devices and Equipment Sector - openPR.com
Earnings Update: Whats the profit margin of Aptiv PLC2026 Rallies & Capital Protection Trading Alerts - baoquankhu1.vn
TPB Stock Analysis: Turning Point Brands Inc drops 14.45% to 74.25 in selloff - Cổng thông tin điện tử tỉnh Lào Cai
Bone Biologics Corp Stock (BBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):